ArrowMark Colorado Holdings’s Ascendis Pharma A/S ASND Stock Holding History

ArrowMark Colorado Holdings’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-12,000	Closed	-$1.35M	–	303
2020 Q1	$1.35M	Hold	12,000	–	–	0.02%	234
2019 Q4	$1.67M	Buy	+12,000	New	+$1.33M	0.01%	252

Other funds holding ASND

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

ArrowMark Colorado Holdings's ASND Position: Q2 2020 in Review

ArrowMark Colorado Holdings sold out of Ascendis Pharma A/S (ASND) in Q2 2020, closing a stake of 12,000 shares — an estimated $1.35M sold.

ArrowMark Colorado Holdings first reported a position in ASND in Q4 2019 and held it in 2 quarters. The position peaked at $1.67M in Q4 2019. 154 funds tracked by Wall St. Rank hold ASND as of Q2 2020.

ArrowMark Colorado Holdings reported no remaining Ascendis Pharma A/S position as of Q2 2020 after selling out during the quarter.
ArrowMark Colorado Holdings sold 12,000 Ascendis Pharma A/S shares in Q2 2020, an estimated $1.35M.
ArrowMark Colorado Holdings first reported a position in Ascendis Pharma A/S in Q4 2019 and held it in 2 quarters.
ArrowMark Colorado Holdings's Ascendis Pharma A/S position peaked at $1.67M in Q4 2019.
154 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2020.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2020, filed 14 Aug 2020.